Hypothyroidism in patients with hepatocellular carcinoma treated by transarterial chemoembolization
β Scribed by Felix Flohr; Jan Harder; Jochen Seufert; Hubert E. Blum; Hans C. Spangenberg
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 43 KB
- Volume
- 47
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
It has been shown previously that erythropoietin expression in uitro by hepatoma cells increases in response to hypoxia. To verify whether hypoxia of the tumor might result in hepatic release of erythropoietin in uiuo, serum erythropoietin concentrations were measured immunoenzymatically in 12 patie
## Abstract ## BACKGROUND. Many liver staging systems have been proposed for patients with hepatocellular carcinoma after locoregional therapy; however, controversies persist regarding which system is the best. In this study, the authors compared the performance of 7 staging systems in a cohort of
## Comparison of 7 Staging Systems for Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization I n a recent article in Cancer, Cho and colleagues 1 suggested that the Cancer of the Liver Italian Program (CLIP) system was the best prognostic system for predicting the survi
## Comparison of 7 Staging Systems for Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization I n a recent article in Cancer, Cho and colleagues 1 suggested that the Cancer of the Liver Italian Program (CLIP) system was the best prognostic system for predicting the survi
Hepatocellular carcinoma (HCC) is one of the most severe sequelae of chronic liver disease. The only potentially curative therapeutic options are surgical resection and orthotopic liver transplantation. In most HCC patients, however, at clinical presentation the tumors are unresectable because of mu